This website uses cookies to enhance the user experience.
||
N

NATTOPHARMA AS987 774 339

Limited company
Etasje 05 Mustads Vei 1 0283 OSLO, Norge

NATTOPHARMA AS

Operating
Direkte og via eierinteresser i andre selskaper å: Utvikle, distribuere og selge ernæringsprodukter og pharmasiprodukter, samt tilknyttede tjenester til dette.
Utvikle, distribuere og selge ernæringsprodukter og pharmasi produkter, samt tilknyttede tjenester m.m., og ha muligheten til å investere i annen virksomhet.

Links

Organization

Chairman of the board
Years since formation
21 years
since Jan 27, 2005
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
350,000
1 share class
Total number of shareholders
1
company
Belongs to group of

Financials

Annual total result 2025
868,686
NOK
Total equity 2025
27,160,467
NOK
Last update: Jun 27, 2026

Management

Board

NameRoleShares
Chairman
1.23 %
indirectly
Board Member-

Others

NameRoleShares
F
FORVIS MAZARS AS
Auditor-

Top 10 individual shareholders

NameRoleShares
-
35.45 %
indirectly
-
23.57 %
indirectly
-
1.6 %
indirectly
-
1.44 %
indirectly
Chairman
1.23 %
indirectly
Last update: Jan 3, 2025

Ownership

Company shareholders

NameShare classTotal number of sharesShare
I
IMMUNOPHARMA AS
NO0010289200
350,000
100 %
Last update: Jun 2, 2025

Group structure

  • Total operating income 2025: NOK 18,004,610
    Operating profit 2025: NOK -20,461,195
    Employees: 15

Financials

in NOK

Summary

Year20252024202320222021
Total operating income
0
29,582,426
196,104,000
71,314,000
95,925,000
Annual Total Result
868,686
35,602,210
110,359,000
109,532,000
-44,429,000
Total assets
32,949,739
47,555,309
234,034,000
285,609,000
237,389,000
Total liabilities
5,789,272
21,263,528
166,284,000
193,217,000
67,238,000
Total equity
27,160,467
26,291,781
67,751,000
92,392,000
170,151,000

P&L

Year20252024202320222021
Total operating income
0
29,582,426
196,104,000
71,314,000
95,925,000
Total operating costs
340,116
4,676,596
79,723,000
77,926,000
124,535,000
Operating result
-340,116
24,905,830
116,381,000
-6,612,000
-28,610,000
Financial income/costs
1,208,802
10,696,379
12,978,000
108,144,000
2,001,000
Profit before tax
868,686
35,602,210
129,359,000
101,532,000
-26,609,000
Total tax & extraordinary income/cost
0
0
19,000,000
-8,000,000
17,820,000
Annual Total Result
868,686
35,602,210
110,359,000
109,532,000
-44,429,000

Balance overview

Year20252024202320222021
Total fixed assets
25,000,000
5,447,024
13,077,000
83,056,000
168,356,000
Total current assets
7,949,739
42,108,285
220,957,000
202,553,000
69,033,000
Total assets
32,949,739
47,555,309
234,034,000
285,609,000
237,389,000
Short term debt
5,789,272
21,263,528
154,426,000
190,285,000
40,474,000
Long term debt
0
0
11,858,000
2,932,000
26,764,000
Total liabilities
5,789,272
21,263,528
166,284,000
193,217,000
67,238,000
Contributed capital
1,050,000
1,050,000
63,111,000
63,111,000
204,321,000
Retained earnings
26,110,467
25,241,781
4,640,000
29,281,000
-34,170,000
Total equity
27,160,467
26,291,781
67,751,000
92,392,000
170,151,000
Total equity and liabilities
32,949,739
47,555,309
234,035,000
285,609,000
237,389,000

Classification

21st company classification
BETA
Industrial large enterprise
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises